(Reuters) -The U.S. Food and Drug Administration is probing the death of a patient who developed harmful antibodies after taking Takeda Pharmaceuticals' blood disorder therapy, the health regulator said on Friday.
The pediatric patient died about 10 months after starting Takeda's drug Adzynma as a preventive therapy, the agency said.
The child had congenital thrombotic thrombocytopenic purpura (cTTP), an inherited condition that causes blood clots in small vessels and can lead to organ damage.
The FDA said the child developed antibodies that blocked the activity of ADAMTS13, an enzyme critical for blood clotting.
Takeda did not immediately respond to Reuters request for comment.
Adzynma, approved in 2023 as the first therapy for cTTP, replaces the ADAMTS13 protein to help prevent dangerous blood clots.
The agency added it has received multiple postmarketing reports of patients developing neutralizing antibodies to ADAMTS13 after treatment with Adzynma.
(Reporting by Kamal Choudhury in Bengaluru; Editing by Vijay Kishore)
最近の投稿
- 1
Ocean side Locations for a Family Excursion - 2Instructions to Expand Your Smash 1500's Presentation: Tips and Deceives
- 3Benin coup thwarted by loyalist troops, president tells nation
- 4The most effective method to Guarantee Simple Availability in Seniors' SUVs
- 5Amy Poehler's podcast is a hit. It's also a Trojan horse for talking about women and aging.
- How will the universe end?
- NASA, in a rare move, cuts space station mission short after an astronaut's medical issue
- Shipping: The Corridors of Trade and the Coming of Another Period
- From Squid Game to Your Party! Six Entertaining Test Games That Will Have You in Join
- All the ways Marjorie Taylor Greene has shifted her approach lately — and why Trump is 'surprised at her'
- Exploring the Mind boggling Universe of Connections: Individual Bits of knowledge
- Help Your Efficiency with These Work area Updates
- The Most Compelling Innovation Developments Somewhat recently
- Vote in favor of your #1 Sort of Convenience for a Family
